🇺🇸 FDA
Pipeline program

Bendamustine 100 mg Powder for concentrate for Solution for Infusion, Truxima 100 mg concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, PREDNISONE BIOGARAN 20 mg, scored tablet, Cyclophosphamide Injection 500 mg., Doxorubicin 2 mg/ml Solution for Injection., Truxima 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Revlimid 5 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Revlimid 20 mg hard capsul

M22-003

Phase 3 small_molecule active

Quick answer

Bendamustine 100 mg Powder for concentrate for Solution for Infusion, Truxima 100 mg concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, PREDNISONE BIOGARAN 20 mg, scored tablet, Cyclophosphamide Injection 500 mg., Doxorubicin 2 mg/ml Solution for Injection., Truxima 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Revlimid 5 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Revlimid 20 mg hard capsul for Follicular Lymphoma is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Follicular Lymphoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials